164 related articles for article (PubMed ID: 33817838)
1. Characterization of a highly neutralizing single monoclonal antibody to botulinum neurotoxin type A.
Brier S; Rasetti-Escargueil C; Wijkhuisen A; Simon S; Marechal M; Lemichez E; Popoff MR
FASEB J; 2021 May; 35(5):e21540. PubMed ID: 33817838
[TBL] [Abstract][Full Text] [Related]
2. A camelid single-domain antibody neutralizes botulinum neurotoxin A by blocking host receptor binding.
Yao G; Lam KH; Weisemann J; Peng L; Krez N; Perry K; Shoemaker CB; Dong M; Rummel A; Jin R
Sci Rep; 2017 Aug; 7(1):7438. PubMed ID: 28785006
[TBL] [Abstract][Full Text] [Related]
3. Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity.
Mazuet C; Dano J; Popoff MR; Créminon C; Volland H
PLoS One; 2010 Aug; 5(8):e12416. PubMed ID: 20865035
[TBL] [Abstract][Full Text] [Related]
4. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.
Levy R; Forsyth CM; LaPorte SL; Geren IN; Smith LA; Marks JD
J Mol Biol; 2007 Jan; 365(1):196-210. PubMed ID: 17059824
[TBL] [Abstract][Full Text] [Related]
5. Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.
Fan Y; Barash JR; Lou J; Conrad F; Marks JD; Arnon SS
J Infect Dis; 2016 May; 213(10):1606-14. PubMed ID: 26936913
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor.
Sharma R; Zhao H; Al-Saleem FH; Ubaid AS; Puligedda RD; Segan AT; Lindorfer MA; Bermudez R; Elias M; Adekar SP; Simpson LL; Taylor RP; Dessain SK
Mol Immunol; 2014 Feb; 57(2):247-54. PubMed ID: 24184879
[TBL] [Abstract][Full Text] [Related]
7. Potent neutralization of botulinum neurotoxin/B by synergistic action of antibodies recognizing protein and ganglioside receptor binding domain.
Chen C; Wang S; Wang H; Mao X; Zhang T; Ji G; Shi X; Xia T; Lu W; Zhang D; Dai J; Guo Y
PLoS One; 2012; 7(8):e43845. PubMed ID: 22952786
[TBL] [Abstract][Full Text] [Related]
8. Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F.
Fu Z; Chen C; Barbieri JT; Kim JJ; Baldwin MR
Biochemistry; 2009 Jun; 48(24):5631-41. PubMed ID: 19476346
[TBL] [Abstract][Full Text] [Related]
9. Botulinum Neurotoxin Serotype A Recognizes Its Protein Receptor SV2 by a Different Mechanism than Botulinum Neurotoxin B Synaptotagmin.
Weisemann J; Stern D; Mahrhold S; Dorner BG; Rummel A
Toxins (Basel); 2016 May; 8(5):. PubMed ID: 27196927
[TBL] [Abstract][Full Text] [Related]
10. Only the complex N559-glycan in the synaptic vesicle glycoprotein 2C mediates high affinity binding to botulinum neurotoxin serotype A1.
Mahrhold S; Bergström T; Stern D; Dorner BG; Åstot C; Rummel A
Biochem J; 2016 Sep; 473(17):2645-54. PubMed ID: 27313224
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin.
Garcia-Rodriguez C; Geren IN; Lou J; Conrad F; Forsyth C; Wen W; Chakraborti S; Zao H; Manzanarez G; Smith TJ; Brown J; Tepp WH; Liu N; Wijesuriya S; Tomic MT; Johnson EA; Smith LA; Marks JD
Protein Eng Des Sel; 2011 Mar; 24(3):321-31. PubMed ID: 21149386
[TBL] [Abstract][Full Text] [Related]
12. Enhancing toxin-based vaccines against botulism.
Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
[TBL] [Abstract][Full Text] [Related]
13. Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain.
Avril A; Miethe S; Popoff MR; Mazuet C; Chahboun S; Rasetti-Escargueil C; Sesardic D; Thullier P; Hust M; Pelat T
BMC Biotechnol; 2015 Sep; 15():86. PubMed ID: 26382731
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of botulinum neurotoxin serotype A1 binding to human SV2A or SV2C receptors.
Azzaz F; Hilaire D; Fantini J
Chem Biol Interact; 2023 Mar; 373():110384. PubMed ID: 36754227
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the monoclonal antibody response to botulinum neurotoxin type A in the complexed and uncomplexed forms.
Zhao H; Nakamura K; Kohda T; Mukamoto M; Kozaki S
Jpn J Infect Dis; 2012; 65(2):138-45. PubMed ID: 22446121
[TBL] [Abstract][Full Text] [Related]
16. Epitope characterization of sero-specific monoclonal antibody to Clostridium botulinum neurotoxin type A.
Corbett CR; Ballegeer E; Weedmark KA; Elias MD; Al-Saleem FH; Ancharski DM; Simpson LL; Berry JD
Hybridoma (Larchmt); 2011 Dec; 30(6):503-10. PubMed ID: 22149274
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B.
Fan Y; Dong J; Lou J; Wen W; Conrad F; Geren IN; Garcia-Rodriguez C; Smith TJ; Smith LA; Ho M; Pires-Alves M; Wilson BA; Marks JD
Toxins (Basel); 2015 Aug; 7(9):3405-23. PubMed ID: 26343720
[TBL] [Abstract][Full Text] [Related]
18. Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B.
Rasetti-Escargueil C; Avril A; Chahboun S; Tierney R; Bak N; Miethe S; Mazuet C; Popoff MR; Thullier P; Hust M; Pelat T; Sesardic D
MAbs; 2015; 7(6):1161-77. PubMed ID: 26381852
[TBL] [Abstract][Full Text] [Related]
19. Crystal Structure of Botulinum Neurotoxin A2 in Complex with the Human Protein Receptor SV2C Reveals Plasticity in Receptor Binding.
Gustafsson R; Zhang S; Masuyer G; Dong M; Stenmark P
Toxins (Basel); 2018 Apr; 10(4):. PubMed ID: 29649119
[TBL] [Abstract][Full Text] [Related]
20. Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A.
Strotmeier J; Mahrhold S; Krez N; Janzen C; Lou J; Marks JD; Binz T; Rummel A
FEBS Lett; 2014 Apr; 588(7):1087-93. PubMed ID: 24583011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
